Metastatic Breast CancerPhase 3CLEOPATRANCT00567190
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
A Phase 3 study testing Pertuzumab, Trastuzumab and Docetaxel in people with Metastatic Breast Cancer, run by Genentech, Inc. at 322 sites in 26 countries.
Trial summary
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Metastatic Breast Cancer
- What is being tested?
- Pertuzumab, Trastuzumab and Docetaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 808 participants
- Where
- 322 sitesin 26 countries
- Study dates
- 12 Feb 2008to 23 Nov 2018
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and candidate for chemotherapy. Participants with measurable and non-measurable disease are eligible (locally recurrent disease must not be amenable to resection with curative intent; participants with de novo Stage IV disease are eligible)
- Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC)
- Left ventricular ejection fraction (LVEF) ≥50 percent (%) at baseline (within 42 days of randomization)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment
Who cannot join
- History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC, which must be stopped prior to randomization)
- History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting
- History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (<)12 months
- History of persistent Grade ≥2 hematologic toxicity resulting from previous adjuvant therapy
- Current peripheral neuropathy of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0, Grade ≥3 at randomization
- History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent
Show all 24Show fewer
- Current clinical or radiographic evidence of central nervous system (CNS) metastases
- Computed tomography (CT) or magnetic resonance imaging (MRI) scan of the brain is mandatory in cases of clinical suspicion of brain metastases
- History of exposure to cumulative doses of anthracyclines
- Current uncontrolled hypertension or unstable angina
- History of congestive heart failure (CHF) of any New York Heart Association (NYHA) criteria, or serious cardiac arrhythmia requiring treatment (exception: atrial fibrillation or paroxysmal supraventricular tachycardia)
- History of myocardial infarction within 6 months of randomization
- History of LVEF decline to below 50% during or after prior trastuzumab neo-adjuvant or adjuvant therapy
- Current dyspnea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy
- Inadequate organ function, as defined in the protocol, within 28 days prior to randomization
- Current severe, uncontrolled systemic disease
- Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment
- Pregnant or lactating women
- History of receiving any investigational treatment within 28 days of randomization
- Current known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
- Receipt of IV antibiotics for infection within 14 days of randomization
- Current chronic daily treatment with corticosteroids (excluding inhaled steroids)
- Known hypersensitivity to any of the study drugs
- Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
Trial locations and contacts
322 sites in 26 countries.
322 sites in 26 countries
United States159 sites
Central Hematology Oncology Medical Group Inc.
Alhambra, California, 91801
Pacific Cancer Medical Center
Anaheim, California, 92801
Comprehensive Blood/Cancer Ctr
Bakersfield, California, 93309
Kaiser Permanente - Baldwin Park
Baldwin Park, California, 91706
Private Practice- Carolyn Hendricks, MD
Bethesda, Maryland, 20817
Tower Cancer Research Foundation
Beverly Hills, California, 90211
St. Vincent Frontier Cancer Center
Billings, Montana, 59101
Boca Raton Comprehensive Cancer Center
Boca Raton, Florida, 33428
Boston Medical Center
Boston, Massachusetts, 02118-2393
Wellmonth Physician Services
Bristol, Virginia, 24201
Brockport-Interlakes Foundation
Brockport, New York, 14420
South Bay Oncology Hematology Partners
Campbell, California, 95008
Canandaigua-Interlakes Found
Canandaigua, New York, 14420
Gabrail Cancer Center
Canton, Ohio, 44718
Florida Cancer Specialists -Cape Coral (Cape Coral Pkwy)
Cape Coral, Florida, 33914
Florida Cancer Specialists - Cape Coral (Del Prado Blvd)
Cape Coral, Florida, 33990
Erlanger Health System; Oncology Research
Chattanooga, Tennessee, 37403
SCRI Tennessee Oncology Chattanooga
Chattanooga, Tennessee, 37404
Oncology Hematology Care Inc
Cincinnati, Ohio, 45242
Hema Onc Conslts-Grant Ave
Columbus, Ohio, 43215
The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc.
Columbus, Ohio, 43219
Hematology Onc Consultants
Columbus, Ohio, 43228
Northwest Oncology/ Hematology Assoc.
Coral Springs, Florida, 33065-5701
Wilshire Oncology Medical Group
Corona, California, 92879
Cons in Med Onc and Hem
Darby, Pennsylvania, 19026
UM Sylvester Deerfield Beach; Sylvester Cancer Ctr
Deerfield Beach, Florida, 33442
Gabrail Cancer Center
Dover, Ohio, 44622
Consultants in Medical Oncology/Hematology
Drexel Hill, Pennsylvania, 19026
Duke University Medical Center
Durham, North Carolina, 27710
Southdale Cancer Clinic U of M Medical Center, Fairview- Edina
Edina, Minnesota, 55435
Elmhurst Hospital
Elmhurst, Illinois, 60126
Florida Cancer Specialists - Englewood
Englewood, Florida, 34223
San Juan Oncology Associates
Farmington, New Mexico, 87401
Florida Cancer Specialists - Fort Myers (New Hampshire Ct)
Fort Myers, Florida, 33901-8101
Florida Cancer Specialists - Broadway
Fort Myers, Florida, 33901
Florida Cancer Specialists; SCRI
Fort Myers, Florida, 33901
Florida Cancer Specialists-Broadway, Fort Myers
Fort Myers, Florida, 33908
Compassionate Cancer Care
Fountain Valley, California, 92708
Pacific Coast Hematology/Oncology Medical Group
Fountain Valley, California, 92708
St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr
Fullerton, California, 92835
Private Practice Robert R. Carroll, Md, Pa
Gainesville, Florida, 32605
Northeast Georgia Medical Center; Oncology Research Dept-5C
Gainesville, Georgia, 30501
Geneva-Interlakes Foundation
Geneva, New York, 14456
Wilshire Onc Med Grp., Inc
Glendora, California, 91741
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49503
Cancer & Hematology Center of West Michigan
Grand Rapids, Michigan, 49546
Hematology Oncology Consultants (NWK)
Granville, Ohio, 43023
Carolina Oncology Specialists, PA - Hickory
Hickory, North Carolina, 28602
Monroe Medical Associates - Hobart
Hobart, Indiana, 46342
St. Mary Medical Center
Hobart, Indiana, 46432
Memorial Cancer Institute
Hollywood, Florida, 33021
Memorial Regional Hospital
Hollywood, Florida, 33021
Park Plaza
Houston, Texas, 77004
Southwest
Houston, Texas, 77008
St. Joseph's
Houston, Texas, 77008
Memorial City-Main Office
Houston, Texas, 77024
Oncology Consultants
Houston, Texas, 77024
St. Luke's
Houston, Texas, 77030
Willowbrook
Houston, Texas, 77070
Carolina BioOncology Institute, PLCC
Huntersville, North Carolina, 28078
Hematology-Oncology of Indiana, Pc
Indianapolis, Indiana, 46260
Uni of Iowa Hospital&Clinic; Holden Comprehens. Cancer Ctr
Iowa City, Iowa, 52242
McLeod Cancer and Blood Center
Johnson City, Tennessee, 37604
NEA Baptist Clinic
Jonesboro, Arkansas, 72401
Katy-Christus St. Catherine
Katy, Texas, 77450
Armstrong County Memorial Hospital
Kittanning, Pennsylvania, 16201
University of Tennessee Cancer Institute;Hem-Onc Consultants
Knoxville, Tennessee, 37920
Wilshire Oncology Medical Group
La Verne, California, 91750
Cancer Center of Acadiana at Lafayette General
Lafayette, Louisiana, 70506
ProHEALTH Care Associates LLP
Lake Success, New York, 11042
Lakeland Regional Cancer Center
Lakeland, Florida, 33804-1057
Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
NW Carolina Onc & Hem
Lenoir, North Carolina, 28645
Southeast Nebraska Cancer Center;; Southeast Nebraska Hematology and Oncology
Lincoln, Nebraska, 68510
St. Barnabas Cancer Center
Livingston, New Jersey, 07039
UCLA
Los Angeles, California, 90024
LAC USC Medical Center
Los Angeles, California, 90033
Cedars- Sinai Medical Center
Los Angeles, California, 90048
Ronald Reagan UCLA Medical Center Clin Lab
Los Angeles, California, 90095
TORI Central Administration
Los Angeles, California, 90095
UCLA Hematology / Oncology Clinic
Los Angeles, California, 90095
UCLA Med Ctr; Pharma Svcs
Los Angeles, California, 90095
Jewish Cancer Care
Louisville, Kentucky, 40245
Central Georgia Hematology Oncology Associates
Macon, Georgia, 31201
Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
Marietta, Georgia, 30060
Jackson Memorial Hospital
Miami, Florida, 33136
University of Miami School of Medicine
Miami, Florida, 33136
US Oncology Research at Minnesota Oncology
Minneapolis, Minnesota, 55404
Minneapolis Oncology Hamatology PA
Minneapolis, Minnesota, 55407-3799
Sutter Gould Medical Foundation; Clinical Research
Modesto, California, 95355
Oncology and Hematology Specialists
Mountain Lakes, New Jersey, 07046
Community Hospital; Pharmacy
Munster, Indiana, 46321
Northwest Oncology
Munster, Indiana, 46321
Monroe Medical Associates
Munster, Indiana, 46375
Hematology Oncology Consultants Ltd
Naperville, Illinois, 60540
Florida Cancer Specialists - Goodlette, Naples
Naples, Florida, 34102
Florida Cancer Specialists - Pine Ridge, Naples
Naples, Florida, 34119
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
Nashville, Tennessee, 37203
The Jones Clinic, PC
New Albany, Mississippi, 38652
Beth Israel Comprehensive Cancer Center Pharmacy
New York, New York, 10011
The Women'sOncology & Wellness Practice
New York, New York, 10016
Conslts in Med Onc (Newtown); Bryn Mawr Health Canc Ctr
Newtown Square, Pennsylvania, 19073
Norfolk Oncology Consultants
Norfolk, Nebraska, 68701
Kaiser Permanente - Oakland
Oakland, California, 94611
Northern Utah Associates
Ogden, Utah, 84403
Mercy Physicians of Oklahoma
Oklahoma City, Oklahoma, 73120
Hematology-Oncology Consultants, Pc
Omaha, Nebraska, 68122
Private Practice
Orlando, Florida, 32804
Ventura County Hematology-Oncology Specialists
Oxnard, California, 93030
UCLA Healthcare/Pasadena Oncology
Pasadena, California, 91105
Wilshire Oncology Medical Group
Pasadena, California, 91750
Breast Cancer Centre at Memorial Hospital West
Pembroke Pines, Florida, 33028
Uni of Pittsburgh; Magee-Women'S Hospital
Pittsburgh, Pennsylvania, 15213
Berkshire Hematology, Oncology Pc
Pittsfield, Massachusetts, 01201
Bay Area Cancer Research Group, LLC
Pleasant Hill, California, 94523
Wilshire Oncology Medical Group
Pomona, California, 91767
Florida Cancer Specialists - Port Charlotte
Port Charlotte, Florida, 33980
Quincy Medical Group
Quincy, Illinois, 62301
Wilshire Oncology Medical Group
Rancho Cucamonga, California, 91730
Consultants Med Onc & Hem
Ridley Park, Pennsylvania, 19078
Upstate Ny Cancer Research & Education Foundation
Rochester, New York, 14623
Community Cancer Center Rutland Regional Medical Center
Rutland, Vermont, 05701
UC Davis Cancer Center; Oncology
Sacramento, California, 95817
Oncology Care Associates PLLC
Saint Joseph, Michigan, 49085
South Texas Oncology Hematology
San Antonio, Texas, 78258
Kaiser Permanente San Diego; Hepatology Research
San Diego, California, 92154
K. Permanente - San Fransisco
San Francisco, California, 94115
K. Permanente - San Jose
San Jose, California, 95119
Sansum Santa Barbara Medical Foundation Clinic
Santa Barbara, California, 93105
Santa Barbara Hematology Oncology Medical Group, Inc.
Santa Barbara, California, 93105
UCLA Hematology/Oncology
Santa Monica, California, 90404
Florida Cancer Specialists; Sarasota
Sarasota, Florida, 34232
HonorHealth Research Institute - Bisgrove
Scottsdale, Arizona, 85258
Christus Schumpert Health System
Shreveport, Louisiana, 71101-1978
Oncology Consultants - Sugar Land
Sugar Land, Texas, 77479
Northwest Medical Specialties
Tacoma, Washington, 98405
Bay Area Oncology
Tampa, Florida, 33607
Medical College of Ohio; Cancer Institute
Toledo, Ohio, 43614
CA Care Associates-OK Oncology and Hematology
Tulsa, Oklahoma, 74104
Cancer Care Assoc-S. Ingo
Tulsa, Oklahoma, 74133
OK Oncology & Hematology PC
Tulsa, Oklahoma, 74136
UCLA / Santa Clarita Valley Cancer Center
Valencia, California, 91355
Kaiser Permanente - Vallejo
Vallejo, California, 94589
Florida Cancer Specialists - Venice (S. Tamiami Tr)
Venice, Florida, 33980
Florida Cancer Specialists - Sunset Lake, Venice
Venice, Florida, 34292
Family Medicine Vincennes
Vincennes, Indiana, 47591
St. Mary Medical Center
Walla Walla, Washington, 99362
K. Permanente - Walnut Creek
Walnut Creek, California, 94596
Central GA Cancer Care
Warner Robins, Georgia, 31088-2259
Georgetown University Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia, 20007
MedStar Washington Hosp Center
Washington D.C., District of Columbia, 20010
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016
Wilshire Oncology Medical Group
West Covina, California, 91790
Cleveland Clinic Florida
Weston, Florida, 33331
University of Kansas; Medical Center & Medical pavilion
Westwood, Kansas, 66205
Innovative clinical research institute/American institute of research
Whittier, California, 90603
Cancer Center of Kansas
Wichita, Kansas, 67214-3728
Midwestern Regional Medical Center; Office of Research
Zion, Illinois, 60099
Japan28 sites
Aichi Cancer Center Hospital, Breast Oncology
Aichi, 464-8681
Chiba Cancer Center; Breast Surgical Oncology
Chiba, 260-8717
National Cancer Center Hospital East; Breast and Medical Oncology
Chiba, 277-8577
Natl Hosp Org Shikoku; Cancer Ctr, Surgery
Ehime, 791-0280
Kitakyushu Municipal Medical Center, Surgery
Fukuoka, 802-0077
National Hospital Organization Kyushu Cancer Center;Breast Oncology
Fukuoka, 811-1395
Gunma University Hospital; Department of Thoracic and Visceral Organ Surgery
Gunma, 371-8511
Sagara Hospital; Breast Surgery
Kagoshima, 892-0833
St. Marianna University School of Medicine Hospital, Breast and Endocrine Surgery
Kanagawa, 216-8511
Tokai University Hospital, Breast and Endocrine Surgery
Kanagawa, 259-1193
Kumamoto City Hospital, Breast and Endocrine Surgery
Kumamoto, 862-8505
Kumamoto Shinto General Hospital; Breast Cancer Center
Kumamoto, 862-8655
Kyoto University Hospital; Breast Surgery
Kyoto, 606-8507
Niigata Cancer Ctr Hospital; Breast Surgery
Niigata, 951-8566
Iwate Med Univ School of Med; Surgery
Numakunai, 020-8505
OSAKA CITY GENERAL HOSPITAL;Medical Oncology
Osaka, 534-0021
National Hospital Organization Osaka National Hospital; Breast Surgery
Osaka, 540-0006
Osaka University Hospital; Breast and Endocrine Surgery
Osaka, 565-0871
Saitama Medical University International Medical Center; Medical Oncology
Saitama, 350-1298
Saitama Cancer Center, Breast Oncology
Saitama, 362-0806
Shizuoka Cancer Center; Female Internal Medicine
Shizuoka, 411-8777
Shizuoka General Hospital; Breast Surgery
Shizuoka, 420-8527
Jichi Medical University; Dept of Clinical Oncology
Tochigi, 329-0498
National Cancer Center Hospital; Breast and Medical Oncology
Tokyo, 104-0045
St. Luke's Internat. Hospital, Breast Surgical Oncology
Tokyo, 104-8560
Tokyo Metropolitan; Komagome Hospital, Surgery
Tokyo, 113-8677
The Cancer Inst. Hosp. of JFCR; Breast Oncology Center
Tokyo, 135-8550
Tokyo Medical Uni. Hospital; Breast Oncology
Tokyo, 160-0023
Brazil19 sites
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, 60336-550
Centro Goiano de Oncologia - CGO
Goiânia, Goiás, 74140-050
Hospital de Caridade de Ijui; Oncologia
Ijuí, Rio Grande do Sul, 98700-000
Hospital Amaral Carvalho
Jaú, São Paulo, 17210-120
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90020-090
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200
Hospital das Clinicas - FMUSP Ribeirao Preto
Ribeirão Preto, São Paulo, 14048-900
Instituto Nacional de Cancer - INCa; Oncologia
Rio de Janeiro, Rio de Janeiro, 20560-120
Hospital Universitario Clementino Fraga Filho - UFRJ; Oncologia
Rio de Janeiro, Rio de Janeiro, 21941-590
Clinica Amo - Assistencia Medica Em Oncologia
Salvador, Estado de Bahia, 41950-610
Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia
Santo André, São Paulo, 09060-650
Iso - Inst. Santista de Oncologia
Santos, São Paulo, 11075-350
Instituto do Cancer Arnaldo Vieira de Carvalho - ICAVC; Pesquisa Clinica
São Paulo, São Paulo, 01221-020
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000
Hospital Perola Byington
São Paulo, São Paulo, 01317-000
Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia
São Paulo, São Paulo, 03102-002
Hospital Estadual do Servidor Publico
São Paulo, São Paulo, 04039-901
Instituto de Oncologia de Sorocaba - CEPOS
Sorocaba, São Paulo, 18030-005
Germany13 sites
Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch
Berlin, 14195
Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie
Bielefeld, 33604
St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe
Cologne, 50935
Universitätsklinikum Essen; Zentrum Für Frauenheilkunde
Essen, 45122
Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie
Halle, 06120
Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
Hamburg, 20246
Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
Heidelberg, 69120
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
Mainz, 55131
Krankenhaus Rheinfelden; Frauenklinik
Rheinfelden, 79618
Robert-Bosch-Krankenhaus; Hämatologie, Onkologie und Palliativmedizin
Stuttgart, 70376
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
Trier, 54290
Universitätsklinik Tübingen; Frauenklinik
Tübingen, 72076
Haematologisch-Onkologische Praxis; Dr. med. Christoph Maintz und Matthias Groschek
Würselen, 52146
United Kingdom11 sites
Broomfield Hospital; Oncology
Chelmsford, CM1 7ET
St James Uni Hospital; Icrf Cancer Medicine Research Unit
Leeds, LS9 7TF
Leicester Royal Infirmary; Dept. of Medical Oncology
Leicester, LE1 5WW
St. Bartholomew'S Hospital; Dept of Medical Oncology
London, EC1A 7BE
Royal Free Hospital; Dept of Oncology
London, NW3 2QG
St George'S Hospital; Oncology Research Office /Oncology Opd
London, SW17 ORE
Charing Cross Hospital; Medical Oncology.
London, W6 8RF
The Clatterbridge Cancer Ctr For Oncolgy
Metropolitan Borough of Wirral, CH63 4JY
Mount Vernon Hospital; Centre For Cancer Treatment
Northwood, HA6 2RN
Royal Cornwall Hospital; Dept of Clinical Oncology
Truro, TR1 3LJ
Southend Hospital; Oncology Dept
Westcliffe-on-sea, SS0 0RY
Italy10 sites
Azienda Sanitaria S. Maria Annunziata; S. C. Oncologia Medica
Antella (FI), Tuscany, 50011
Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina
Brescia, Lombardy, 25123
Ospedale Antonio Perrino; Oncologia Medica
Brindisi, Apulia, 72100
Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo
Candiolo, Piedmont, 10060
Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica
Chieti, Abruzzo, 66100
Ausl Frosinone - Ospedale Umberto I; Divisione Di Oncologia
Frosinone, Lazio, 03100
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
Meldola, Emilia-Romagna, 47014
Ospedale Misericordia E Dolce; Oncologia Medica
Prato, Tuscany, 59100
Ospedale Di Macerata; Oncologia
Province of Macerata, The Marches, 62100
Ospedale Provinciale Santa Maria delle Croci
Ravenna, Emilia-Romagna, 48100
Russia9 sites
Ivanovo Regional Oncology Dispensary
Ivanovo, 153040
Regional Oncology Hospital Of Kursk; Chemotherapy
Kislino, Kursk Region, 305524
Blokhin Cancer Research Center; Combined Treatment
Moscow, 115478
Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy
Moscow, 115478
Omsk Region Clinical Oncology Dispensary; 1St Sergical Department
Omsk, 644013
State Inst. Of Healthcare Orenburg Regional Clinical Oncology Dis
Orenburg, 460021
FSBI"National Medical Research Center of Oncology named after N.N.Petrov" MHRF
Saint Petersburg, Sankt-Peterburg, 197758
SBI of Healthcare Leningrad Regional Oncology Dispensary
Saint Petersburg, 191104
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
Samara, 443031
Spain9 sites
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
A Coruña, 15006
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Barcelona, 08035
Hospital Duran i Reynals; Oncologia
Barcelona, 08907
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
Jaén, 23007
Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia
Lleida, 25198
Centro Oncologico MD Anderson Internacional; Servicio de Oncologia
Madrid, 28033
Hospital Universitario 12 de Octubre; Servicio de Oncologia
Madrid, 28041
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
Málaga, 29010
Hospital Universitario de Canarias;servicio de Oncologia
San Cristóbal de La Laguna, Tenerife, 38320
France8 sites
Centre Oncologie Du Pays Basque
Bayonne, 64100
Clinique Tivoli; Sce Radiotherapie
Bordeaux, 33000
Centre Georges Francois Leclerc; Oncologie 3
Dijon, 21079
Centre Hospitalier Departemental Les Oudairies
La Roche-sur-Yon, 85925
Centre Jean Bernard
Le Mans, 72015
Centre Antoine Lacassagne; Hopital De Jour A2
Nice, 06189
Ico Rene Gauducheau; Oncologie
Saint-Herblain, 44805
Groupe Hospitalier Sud; Oncologie Radiotherapie
Salouël, 80480
Argentina7 sites
Sanatorio Güemes; Oncología
Buenos Aires, 1180
Centro de Oncologia e Investigacion Buenos Aires (COIBA)
Buenos Aires, B1884BBF
Instituto Medico Especializado (IME); Oncologia
Caba, 1405
Center Instituto Médico Privado I.M.P.; Oncology
Chaco-resistencia, 3400
Policlinica Privada Site la Plata SA; Oncology
La Plata, B1902CMK
Unidad Oncológica De Neuquén
Neuquén, Q8300HDH
Hosp Provincial D. Centenarios; Oncology Dept
Rosario, S2002KDS
Thailand6 sites
Chulalongkorn Hospital; Medical Oncology
Bangkok, 10330
National Cancer Inst.
Bangkok, 10400
Rajavithi Hospital; Division of Medical Oncology
Bangkok, 10400
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
Bangkok, 10400
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
Bangkok, 10700
Songklanagarind Hospital; Department of Oncology
Songkhla, 90110
China5 sites
Jilin Cancer Hospital
Changchun, 130012
Fuzhou General Hospital, PLA Nanjing Military Area Command
Fuzhou, 110016
Zhejiang Cancer Hospital
Hangzhou, 310022
Shanghai First People's Hospital
Shanghai, 200080
Fudan University Shanghai Cancer Center
Shanghai, 200120
Poland5 sites
Samodzielny Publiczny Kliniczny Nr 1 W Lublinie; Klinika Chirurgii Onkologicznej
Lublin, 20-081
COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
Lublin, 20-090
Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu
Poznan, 60-569
Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych
Szczecin, 71-730
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
Warsaw, 02-781
South Korea5 sites
National Cancer Center; Medical Oncology
Gyeonggi-do, 410-769
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
Seoul, 03080
Yonsei Uni College of Medicine, Severance Hospital; Internal Medicine Dept.
Seoul, 120-752
Samsung Medical Centre; Division of Hematology/Oncology
Seoul, 135-710
Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
Seoul, 138-736
Ecuador4 sites
Solca Guayaquil- Sociedad de Lucha Contra El Cáncer; Oncology
Guayaquil, EC090112
Teodoro Maldonado Carbo Hospital; Oncology Service
Guayaquil, EC090150
Hospital Carlos Andrade Marin; Servicio de Oncología
Quito, 2569
Hospital Solca Quito; Oncologia
Quito, EC170124
Guatemala3 sites
Centro Oncologico S.A.
Guatemala City, 01010
Grupo Angeles
Guatemala City, 01015
Therapeutic Research Inst. & Lab S.A. (Trial)
Guatemala City, 01015
Latvia3 sites
Daugavpils Regional Hospital
Daugavpils, 5417
Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs
Riga, LV 1079
P.Stradins Clinical University Hospital, Oncology Centre
Riga, LV-1002
North Macedonia3 sites
Clinical Hospital; Oncology Department
Bitola, 7000
Institute of Radiotherapy Oncology
Skopje, 1000
Private Health Organization Acibadem Sistina Hospital
Skopje, 1000
Philippines3 sites
Cebu Cancer Institute; Perpetual Succour Hospital
Cebu City, 6000
Veterans Memorial Medical Center; Oncology
Quezon City, 1101
St Luke'S Medical Centre; Oncology
Quezon City, 1114
Croatia2 sites
Clinical Hospital Sisters of Mercy
Zagreb, 10000
University Hospital Centre Zagreb; Clinic For Oncology
Zagreb, 10000
Finland2 sites
Tampere University Hospital; Dept of Oncology
Tampere, 33520
Turku Uni Central Hospital; Oncology Clinics
Turku, 20520
Hong Kong2 sites
Pamela Youde Nethersole Eastern Hospital; Clinical Oncology
Hong Kong
Prince of Wales Hosp; Dept. Of Clinical Onc
Shatin
Mexico2 sites
Hospital Angeles Metropolitano; Room 220
Mexico City, Mexico CITY (federal District), 06760
Centro Oncologico Estatal ISSEMYM
Toluca, 50180
Singapore2 sites
National University Hospital; National University Cancer Institute, Singapore (NCIS)
Singapore, 119228
National Cancer Centre; Medical Oncology
Singapore, 169610
About this study
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Participants could have received one prior hormonal treatment for MBC. Participants may have received systemic breast cancer treatment in the neo-adjuvant or adjuvant setting, provided that the participant had experienced a disease-free interval (DFI) of greater than or equal to (≥)12 months from completion of adjuvant systemic treatment (excluding hormonal therapy) to metastatic diagnosis. Participants may have received trastuzumab and/or a taxane during the neo-adjuvant or adjuvant treatment.
Participants were randomized in 1:1 ratio to receive either pertuzumab or placebo, along with trastuzumab and docetaxel once every 3 weeks (q3w), during the treatment phase of the study until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. Participants in the Placebo arm were not allowed to receive open-label pertuzumab after discontinuation from study treatment. However, if any analysis of overall survival had met the predefined criteria for statistical significance, participants in the Placebo arm still on treatment were offered the option to receive open-label pertuzumab in addition to other study medications.
- Conditions
- Metastatic Breast Cancer
- Being tested
- Pertuzumab, Placebo, Trastuzumab, Docetaxel
- Keywords
- Herceptin, Breast cancer, MBC, Taxotere, HER2, HER2 positive breast cancer, HER2 + breast cancer, HER2-positive, HER2-positive metastatic breast cancer
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PertuzumabDrug
Also called Perjeta, RO4368451, RG1273
Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
PlaceboDrug
Placebo (matching pertuzumab) was administered intravenously.
TrastuzumabDrug
Also called Herceptin
Trastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination.
DocetaxelDrug
Also called Taxotere
Docetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician.
| Study group | Role | What they receive |
|---|---|---|
| Pertuzumab + Trastuzumab + Docetaxel | Experimental | Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination. Receives: Drug: Pertuzumab; Drug: Trastuzumab; Drug: Docetaxel |
| Placebo + Trastuzumab + Docetaxel | Placebo comparator | Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination. Receives: Drug: Placebo; Drug: Trastuzumab; Drug: Docetaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival (PFS) Determined by an Independent Review Facility
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
Measured: Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months)
Secondary outcomes (16)
Overall Survival
Overall survival (OS) was the time from randomization to death from any cause, using Kaplan-Meier methodology. Survival data was collected every 18 weeks during the post-treatment follow-up period until death, loss to follow-up, or withdrawal of consent. Those who were alive, lost to follow up, or withdrew consent were censored at the latest date they participated in the study; those without post-baseline data were censored at 1 day. OS analyses were planned to take place at the primary completion date (First Interim), after 385 deaths (Event-Driven Final), and at the end of study (End-of-Study). A second interim OS analysis was planned due to a formal request from the European Medicines Agency. Median [range] time in weeks on study at each OS analysis (Pertuzumab vs. Placebo): First: 77.1 [0.7-165.3] vs. 73.1 [0.4-165.3]; Second: 117.1 [0.7-207.9] vs. 105.9 [0.4-207.9]; Event-Driven Final: 189.9 [0.7-304.1] vs. 140.5 [0.4-301.6]; End-of-Study: 201.8 [0.7-520.0] vs. 138.0 [0.4-514.7].
Measured: From randomization to death from any cause, up to each respective analysis data cut-off date (see the Description field for the median time on study per treatment arm)
Progression-Free Survival (PFS) Determined by the Investigator
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by the investigator using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without PD or who had not died within 18 weeks of their last investigator-determined, progression-free tumor assessment were censored at the date of the last investigator tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
Measured: Tumor assessments every 9 weeks from randomization to investigator-determined PD or death from any cause, whichever occurred first (median [range] time on study in pertuzumab vs. placebo arms: 201.8 [0.7-520.0] weeks vs. 138.0 [0.4-514.7] weeks)
Objective Response Determined by an Independent Review Facility
An objective response was defined as the percentage of participants with confirmed best overall response of complete response (CR) or partial response (PR) determined by an independent review facility (IRF) using RECIST v1.0 on two consecutive occasions ≥4 weeks apart. For target lesions, CR: disappearance of all target lesions; PR: ≥30% decrease in the sum of the longest diameter (LD) of target lesions (baseline sum LD as reference); PD: ≥20% increase in the sum of the LD of target lesions (smallest sum of the LD recorded as reference) or appearance of ≥1 new lesion; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase for PD. For non-target lesions, CR: disappearance of all non-target lesions; Incomplete/SD: persistence of ≥1 non-target lesions; PD: unequivocal progression of existing non-target lesions. 95% confidence intervals (CI) were calculated only for clinical responses using the Pearson-Clopper method.
Measured: Tumor assessments every 9 weeks from Baseline until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Duration of Objective Response Determined by an Independent Review Facility
Duration of objective response (estimated using the Kaplan-Meier method) was defined as the time from the initial confirmed complete response (CR) or partial response (PR), the date of tumor assessment at which the CR/PR was first detected by the independent review facility (IRF) using RECIST version 1.0, until the date of IRF-determined progressive disease (PD), death from any cause within 18 weeks of the last tumor assessment, or first administration of next line of anti-cancer therapy (whichever occurred first). If the visit when the initial CR or PR was observed spanned multiple dates, the latest date was used. Only participants in the ITT analysis population with an IRF-determined objective response (CR or PR), observed prior to IRF-assessed PD, death or next line of anti-cancer therapy, were included in the analysis. Participants who did not progress or die after they had a confirmed response were censored at the date of their last IRF-evaluable tumor measurement.
Measured: From initial IRF-confirmed objective response until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Time to Symptom Progression
Time to symptom progression was defined as the time from randomization to the first symptom progression as measured by the Functional Assessment of Cancer Therapy-for patients with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contains 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer patients (breast cancer subscale [BCS]). All items in the questionnaire were rated by the patient on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96. A higher score indicates better perceived quality of life. A positive change score from baseline indicates improvement. Symptom progression was defined as a decrease from baseline of 5 points or more.
Measured: Every 9 weeks from Baseline until investigator-determined progressive disease, up to the primary completion date (up to 3 years, 3 months)
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events, by Most Severe Intensity (According to NCI-CTCAE v3.0) During the Treatment Period
Adverse event (AE) severity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0 (NCI-CTCAE v3.0); if the AE was not specifically listed, the following grades of severity were used: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening or disabling; and Grade 5 = death. Severe and serious are not synonymous. Severity refers to the intensity of an AE, whereas a serious AE must meet criteria set out in the protocol; both were independently assessed for each AE. Only the most severe intensity was counted for multiple occurrences of the same AE in one participant. AEs reported prior to first crossover treatment were included in the Placebo arm, and in the Crossover arm after that date, for participants who crossed over from placebo to pertuzumab. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks.
Measured: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Adverse Events by Severity (NCI-CTCAE v3.0 All Grades and Grades 3 to 5) Per 100 Patient-Years of Exposure During the Treatment Period
Adverse event (AE) severity, including serious and non-serious AEs, was assessed according to the NCI-CTCAE version 3.0; if the AE was not specifically listed, the following grades of severity were used: Grade 1 is mild; Grade 2 is moderate; Grade 3 is severe; Grade 4 is life-threatening or disabling; and Grade 5 is death. Multiple occurrences of the same AE in 1 participant were counted multiple times. Only AEs that started during the overall study treatment period were included. The cutoff date for inclusion of events and for calculation of patient-years was the date of the most recent follow-up of the participant, defined as the last available date during the treatment period, excluding pre-treatment and safety follow-up data. Confidence intervals were calculated assuming the number of events followed a Poisson distribution. Data reported prior to the date of first crossover treatment were included under the Placebo arm for participants who crossed over from placebo to pertuzumab.
Measured: From Baseline to 42 days after the last dose of study treatment (total patient-years of exposure on study treatment in Placebo vs. Pertuzumab arms: 526.81 vs. 989.88 patient-years)
Cardiac-Related AEs to Monitor: Number of Participants Who Experienced at Least One Symptomatic Left Ventricular Dysfunction (LVD), Any LVD, or Serious AE Suggestive of Congestive Heart Failure by Severity During the Treatment Period
Cardiac-related adverse events (AEs) to monitor during the study included investigator-assessed symptomatic left ventricular dysfunction (LVD), any LVD, or a serious adverse event (SAE) suggestive of congestive heart failure (CHF). All cardiac-related AEs were graded for severity according to NCI-CTCAE v3.0. Asymptomatic (Grades 1-2) and symptomatic (Grades 3-5) left ventricular systolic dysfunction (LVSD) both coded to the MedDRA preferred term LVD. Investigator-assessed events of symptomatic LVD were also graded for severity of symptoms according to Classes I (least severe) to IV (most severe) of the New York Heart Association (NYHA) Classification. SAEs suggestive of CHF were identified as serious events from the Standardized MedDRA Query (SMQ) (Wide) 'Cardiac Failure'. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks.
Measured: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Number of Participants Who Experienced at Least One Adverse Event to Monitor (Excluding Cardiac-Related AEs) by Severity During the Treatment Period
The clinical diagnoses listed in this table, excluding cardiac safety (summarized separately), were also selected as adverse events (AEs) to monitor based on clinical and nonclinical data for pertuzumab and the safety profile established for trastuzumab, monoclonal antibodies in general, and potential effects associated with HER receptor inhibition. Search strategies were defined by single or aggregate MedDRA Preferred Terms (PT) through Standardized MedDRA Queries (SMQ), where possible, or based on Roche AE Group Terms (AEGT). Diarrhoea AEs: High-Level Term (HLT) 'Diarrhoea (excl. infective)' and PT 'Diarrhoea infectious'. Leukopenic and Febrile Neutropenic Infections: AEs from 'Infections \& Infestations' with start ≤14 days after start date of Grade ≥3 AEs in SMQ(narrow) 'Leukopenia' or PT 'Febrile neutropenia', respectively. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks.
Measured: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Participants Who Experienced at Least One Adverse Event Leading to Discontinuation of Any or All Study Medication
Participants could continue study treatment with pertuzumab/placebo plus trastuzumab when docetaxel was discontinued due to an adverse event (AE). Discontinuation of pertuzumab/placebo or trastuzumab due to an AE led to discontinuation of all study medication. The number of participants who discontinued any study medication due to an AE includes those who discontinued all study medication and those who discontinued docetaxel only and then continued on targeted therapy (note: some of these participants may have subsequently discontinued all treatment due to a separate AE). Multiple occurrences of the same adverse event in 1 participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for those who crossed over from placebo to pertuzumab. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks.
Measured: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication
Pertuzumab, trastuzumab, and docetaxel administration could have been delayed to assess or treat adverse events (AEs). Docetaxel dose reduction was allowed for myelosuppression, hepatic dysfunction, and other toxicities. No dose reduction was allowed for pertuzumab or trastuzumab. Multiple occurrences of the same adverse event in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks
Measured: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Number of Participants Who Experienced at Least One Adverse Event During the Post-Treatment Follow-Up Period
The post-treatment period was defined as the period following the treatment discontinuation visit. Only the following new adverse events (AEs) should have been reported during the post-treatment follow-up period: 1. Cardiac events (regardless of causality or seriousness) that started up to 1 year after the last dose, except for symptomatic left ventricular systolic dysfunction (regardless of causality) that started up to 3 years after the last dose; and 2. Treatment-related serious AEs, regardless of start date. AEs are listed by Medical Dictionary for Regulatory Activities, Version 21.1 (MedDRA v21.1) System Organ Class (SOC) and Preferred Term (PT); PTs fall under the SOC that is listed immediately above it in the table. Multiple occurrences of the same AE in one participant was counted only once. AEs reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab.
Measured: From Day 43 after discontinuation of all study medication to end of post-treatment follow-up period (up to 3 years)
Number of Participants by Categories for the Maximum Absolute Decrease From Baseline in LVEF Value During the Treatment Period
All participants were required to have an left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Data reported prior to first crossover treatment were included in the Placebo arm, and after that date in the Crossover arm, for participants who crossed over from placebo to pertuzumab. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks.
Measured: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Baseline LVEF Value and Change in LVEF From Baseline at Maximum Absolute Decrease Value During the Treatment Period
All participants were required to have a left ventricular ejection fraction (LVEF) ≥50% at baseline, as measured by echocardiogram (preferred) or multiple-gated acquisition (MUGA) scan. The same method of LVEF assessment and the same institution/facility used at baseline was used throughout the study, to the extent possible. The baseline value was defined as the last valid value recorded during the pre-treatment period before or on study Day 1. The maximum absolute decrease in LVEF value was defined as the lowest post-baseline value up to the end of the overall study treatment period. Only data reported prior to the date of first crossover treatment were included for participants who crossed over from placebo to pertuzumab.
Measured: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks)
Number of Participants With Laboratory Abnormalities in Blood Biochemistry Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
Clinical laboratory tests for blood biochemistry parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks. ALP = alkaline phosphatase; GGT = gamma-glutamyl transferase; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = serum glutamic-pyruvic transaminase
Measured: On Day 1 of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Number of Participants With Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
Clinical laboratory tests for hematology parameters were performed at local laboratories; any abnormal values (High or Low) were based on local laboratory normal ranges. Laboratory abnormalities are presented by the highest grade according to NCI-CTCAE v3.0. Not every abnormal laboratory value qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks; Crossover: 129.9 [0.3-322.3] weeks. INR = International Normalized Ratio; PTT = partial thromboplastin time; WBC = white blood cell
Measured: On Day 1 (and Day 8 for some measures) of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2007 (estimated)
- Study start12 Feb 2008
- Primary completion13 May 2011
- Study completion23 Nov 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Metastatic Breast CancerStudies of the same condition, open and under way.
- More trials run by Genentech, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 808 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genentech, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Hoffmann-La Roche
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Genentech, Inc./Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00567190
- Sponsor's protocol ID
- TOC4129g
- Other IDs
- WO20698, 2007-002997-72
- Acronym
- CLEOPATRA
- Status last verified
- Dec 2019
- First submitted
- 3 Dec 2007
- Last updated
- 13 Dec 2019
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
PubMed 22149875Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortes J; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
PubMed 32171426Miles D, Im YH, Fung A, Yoo B, Knott A, Heeson S, Beattie MS, Swain SM. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017 Nov 1;28(11):2761-2767. doi: 10.1093/annonc/mdx406.
PubMed 29112701Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017 Apr 1;28(4):761-768. doi: 10.1093/annonc/mdw695.
PubMed 28057664Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7.
PubMed 27964843Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
PubMed 25693012Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20.
PubMed 25332247Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortes J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014 Jun;25(6):1116-21. doi: 10.1093/annonc/mdu133. Epub 2014 Mar 31.
PubMed 24685829Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. Epub 2013 Oct 16.
PubMed 24129974Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013 Oct;24(10):2630-2635. doi: 10.1093/annonc/mdt274. Epub 2013 Jul 17.
PubMed 23868905Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. Epub 2013 Apr 18.
PubMed 23602601Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.
PubMed 21147694
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
- ClinicalTrials.gov ID
- NCT00567190
- Acronym / sponsor ID
- CLEOPATRA / TOC4129g
- Conditions
- Metastatic Breast Cancer
- Keywords
- Herceptin, Breast cancer, MBC, Taxotere, HER2, HER2 positive breast cancer, HER2 + breast cancer, HER2-positive
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 808 participants (actual)
- Lead sponsor
- Genentech, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Hoffmann-La Roche
- Study start
- 12 Feb 2008 (actual)
- Primary completion
- 13 May 2011 (actual)
- Study completion
- 23 Nov 2018 (actual)
- First posted
- 4 Dec 2007 (estimated)
- Results
- Posted 13 Sep 2012
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was a Phase III, randomized, double-blind, placebo-controlled, multicenter international clinical trial conducted to investigate the use of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Participants could have received one prior hormonal treatment for MBC. Participants may have received systemic breast cancer treatment in the neo-adjuvant or adjuvant setting, provided that the participant had experienced a disease-free interval (DFI) of greater than or equal to (≥)12 months from completion of adjuvant systemic treatment (excluding hormonal therapy) to metastatic diagnosis. Participants may have received trastuzumab and/or a taxane during the neo-adjuvant or adjuvant treatment.
Participants were randomized in 1:1 ratio to receive either pertuzumab or placebo, along with trastuzumab and docetaxel once every 3 weeks (q3w), during the treatment phase of the study until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. Participants in the Placebo arm were not allowed to receive open-label pertuzumab after discontinuation from study treatment. However, if any analysis of overall survival had met the predefined criteria for statistical significance, participants in the Placebo arm still on treatment were offered the option to receive open-label pertuzumab in addition to other study medications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pertuzumab + Trastuzumab + Docetaxel | Experimental | Drug: Pertuzumab, Drug: Trastuzumab, Drug: DocetaxelParticipants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination. |
| Placebo + Trastuzumab + Docetaxel | Placebo comparator | Drug: Placebo, Drug: Trastuzumab, Drug: DocetaxelParticipants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and candidate for chemotherapy. Participants with measurable and non-measurable disease are eligible (locally recurrent disease must not be amenable to resection with curative intent; participants with de novo Stage IV disease are eligible)
- Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC)
- Left ventricular ejection fraction (LVEF) ≥50 percent (%) at baseline (within 42 days of randomization)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective form of contraception and to continue its use for the duration of study treatment and for at least 7 months after the last dose of study treatment
Key exclusion criteria (24 listed)
- History of anti-cancer therapy for MBC (with the exception of one prior hormonal regimen for MBC, which must be stopped prior to randomization)
- History of approved or investigative tyrosine kinase/HER inhibitors for breast cancer in any treatment setting, except trastuzumab used in the neoadjuvant or adjuvant setting
- History of systemic breast cancer treatment in the neo-adjuvant or adjuvant setting with a disease-free interval from completion of the systemic treatment (excluding hormonal therapy) to metastatic diagnosis of less than (<)12 months
- History of persistent Grade ≥2 hematologic toxicity resulting from previous adjuvant therapy
- Current peripheral neuropathy of National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0, Grade ≥3 at randomization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PertuzumabAlso: Perjeta, RO4368451, RG1273Pertuzumab was administered as an intravenous (IV) loading dose of 840 milligrams (mg) q3w on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. | Drug | Pertuzumab + Trastuzumab + Docetaxel |
| PlaceboPlacebo (matching pertuzumab) was administered intravenously. | Drug | Placebo + Trastuzumab + Docetaxel |
| TrastuzumabAlso: HerceptinTrastuzumab was administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. | Drug | Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel |
| DocetaxelAlso: TaxotereDocetaxel was administered as an IV dose of 75 milligrams per square meter of body surface area (mg/m^2) q3w on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) q3w on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, unmanageable toxicity, or study termination. On or prior to Cycle 6, docetaxel was only to be discontinued for progressive disease or unmanageable toxicity. After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. | Drug | Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel |
Primary outcome
Progression-Free Survival (PFS) Determined by an Independent Review Facility
Time frame: Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months)
PFS was defined as the time from randomization to first documented radiographical progressive disease (PD), as determined by an independent review facility (IRF) using RECIST version 1.0, or death from any cause (within 18 weeks of last tumor assessment), whichever occurred first (Kaplan-Meier method). For target lesions, PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum of the LD recorded since treatment started or the appearance of ≥1 new lesion. For non-target lesions, PD was defined as the appearance of ≥1 new lesion or unequivocal progression of existing lesions. Participants without IRF-determined PD or who had not died within 18 weeks of their last IRF-determined, progression-free tumor assessment were censored at the date of the last IRF-reviewed, evaluable tumor assessment; those with no post-baseline tumor assessment and who had not died within 18 weeks of baseline were censored at 1 day.
16 secondary outcomes
Overall Survival
Time frame: From randomization to death from any cause, up to each respective analysis data cut-off date (see the Description field for the median time on study per treatment arm)
Progression-Free Survival (PFS) Determined by the Investigator
Time frame: Tumor assessments every 9 weeks from randomization to investigator-determined PD or death from any cause, whichever occurred first (median [range] time on study in pertuzumab vs. placebo arms: 201.8 [0.7-520.0] weeks vs. 138.0 [0.4-514.7] weeks)
Objective Response Determined by an Independent Review Facility
Time frame: Tumor assessments every 9 weeks from Baseline until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Duration of Objective Response Determined by an Independent Review Facility
Time frame: From initial IRF-confirmed objective response until IRF-determined progressive disease (PD), death, or first administration of next line of anti-cancer therapy (whichever occurred first), up to the primary completion date (up to 3 years, 3 months)
Time to Symptom Progression
Time frame: Every 9 weeks from Baseline until investigator-determined progressive disease, up to the primary completion date (up to 3 years, 3 months)
Overall Number of Participants Who Experienced at Least One Adverse Event, Including Serious and Non-Serious Adverse Events, by Most Severe Intensity (According to NCI-CTCAE v3.0) During the Treatment Period
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Adverse Events by Severity (NCI-CTCAE v3.0 All Grades and Grades 3 to 5) Per 100 Patient-Years of Exposure During the Treatment Period
Time frame: From Baseline to 42 days after the last dose of study treatment (total patient-years of exposure on study treatment in Placebo vs. Pertuzumab arms: 526.81 vs. 989.88 patient-years)
Cardiac-Related AEs to Monitor: Number of Participants Who Experienced at Least One Symptomatic Left Ventricular Dysfunction (LVD), Any LVD, or Serious AE Suggestive of Congestive Heart Failure by Severity During the Treatment Period
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Number of Participants Who Experienced at Least One Adverse Event to Monitor (Excluding Cardiac-Related AEs) by Severity During the Treatment Period
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Participants Who Experienced at Least One Adverse Event Leading to Discontinuation of Any or All Study Medication
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Overall Number of Participants Who Experienced at Least One Adverse Event That Resulted in Interruption or Modification of Any Study Medication
Time frame: Placebo arm: Baseline to last dose of study treatment +42 days (or crossover date); Pertuzumab arm: Baseline to last dose of study treatment +42 days; Crossover arm: Crossover date to last dose of study treatment +42 days (see Description - time per arm)
Number of Participants Who Experienced at Least One Adverse Event During the Post-Treatment Follow-Up Period
Time frame: From Day 43 after discontinuation of all study medication to end of post-treatment follow-up period (up to 3 years)
Number of Participants by Categories for the Maximum Absolute Decrease From Baseline in LVEF Value During the Treatment Period
Time frame: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Baseline LVEF Value and Change in LVEF From Baseline at Maximum Absolute Decrease Value During the Treatment Period
Time frame: Every 9 weeks from the date of randomization until Treatment Discontinuation Visit (median [range] time on study treatment per arm: Placebo: 49.3 [0.3-514.7] weeks; Pertuzumab: 75.7 [0.6-519.6] weeks)
Number of Participants With Laboratory Abnormalities in Blood Biochemistry Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
Time frame: On Day 1 of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Number of Participants With Laboratory Abnormalities in Hematology Tests by Highest Grade According to NCI-CTCAE v3.0 During the Treatment Period
Time frame: On Day 1 (and Day 8 for some measures) of every treatment cycle (1 cycle is 21 days) until Treatment Discontinuation Visit (see Description for time on study treatment per arm)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2019.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 22149875Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.
- Derived from this study: PubMed 32171426Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortes J; CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12.
- Derived from this study: PubMed 29112701Miles D, Im YH, Fung A, Yoo B, Knott A, Heeson S, Beattie MS, Swain SM. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017 Nov 1;28(11):2761-2767. doi: 10.1093/annonc/mdx406.
- Derived from this study: PubMed 28057664Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017 Apr 1;28(4):761-768. doi: 10.1093/annonc/mdw695.
- Derived from this study: PubMed 27964843Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7.
- Derived from this study: PubMed 25693012Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
- Derived from this study: PubMed 25332247Baselga J, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20.
- Derived from this study: PubMed 24685829Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, Cortes J. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014 Jun;25(6):1116-21. doi: 10.1093/annonc/mdu133. Epub 2014 Mar 31.
- Derived from this study: PubMed 24129974Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. Epub 2013 Oct 16.
- Derived from this study: PubMed 23868905Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM. Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. Ann Oncol. 2013 Oct;24(10):2630-2635. doi: 10.1093/annonc/mdt274. Epub 2013 Jul 17.
- Derived from this study: PubMed 23602601Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. Epub 2013 Apr 18.
- Derived from this study: PubMed 21147694Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clin Breast Cancer. 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065.
Related trials for Metastatic Breast Cancer
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruiting
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
Breast Cancer, Breast Neoplasms
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
RecruitingPhase 1/2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Metastatic Breast Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Genentech, Inc./Hoffmann-La Roche
322 sites in 26 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pertuzumab, Trastuzumab and Docetaxel in people with Metastatic Breast Cancer, run by Genentech, Inc. at 322 sites in 26 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 322 sites in United States, Japan, Brazil, Germany, United Kingdom and 21 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Sep 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (PFS) Determined by an Independent Review Facility (time frame: Tumor assessments every 9 weeks from randomization to IRF-determined PD or death from any cause, whichever occurred first, up to the primary completion date (up to 3 years, 3 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00567190, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2019.